News from xtl biopharmaceuticals ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 01, 2018, 10:09 ET XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update

TL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Jul 24, 2018, 09:09 ET XTL Biopharmaceuticals Reports First Half 2018 Financial Results & Provides Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments ...


May 29, 2018, 05:37 ET XTL Biopharmaceuticals Reports First Quarter 2018 Financial Results & Provides Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments ...


Dec 06, 2017, 11:08 ET XTL Biopharmaceuticals Ltd. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Nov 27, 2017, 09:30 ET XTL Biopharmaceuticals Reports Third Quarter 2017 Financial Results

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Oct 23, 2017, 11:23 ET XTL Biopharmaceuticals Receives Notification From NASDAQ Regarding Continuing Listing Requirements

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments ...


Sep 26, 2017, 09:23 ET XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd.(NASDAQ: XTLB) (TASE: XTLB.TA)("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Sep 12, 2017, 09:00 ET XTL Biopharmaceuticals Unveils Additional Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Jun 15, 2017, 09:00 ET XTL Biopharmaceuticals Reports First Quarter 2017 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Apr 27, 2017, 09:50 ET XTL Biopharmaceuticals Appoints Mr. Alex Rabinovich to its Board of Directors

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Mar 30, 2017, 08:55 ET XTL Biopharmaceuticals Reports 2016 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Mar 22, 2017, 09:22 ET XTL Biopharmaceuticals Announces Closing of $2.8 Million Private Placement From Existing Investors

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Mar 07, 2017, 11:40 ET XTL Biopharmaceuticals Announces $2.8 Million Private Placement From Existing Investors

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Mar 01, 2017, 07:30 ET XTL Biopharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Listing Requirement

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Feb 17, 2017, 07:00 ET XTL Biopharmaceuticals Announces $2.5 Million Registered Direct Offering

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) (TASE:XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Feb 13, 2017, 08:08 ET XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome

Dr. Robert I. Fox and Professor Simon Bowman are world-renowned rheumatologists and experts in Sjogren's syndrome XTL Biopharmaceuticals Ltd., is a...


Jan 25, 2017, 07:30 ET XTL Biopharmaceuticals Announces Ratio Change of its Depositary Receipt Program

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Jan 05, 2017, 08:30 ET XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjögren's Syndrome

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing treatments...


Dec 19, 2016, 08:00 ET XTL Biopharmaceuticals to Present at Biotech Showcase

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Dec 06, 2016, 08:30 ET XTL Biopharmaceuticals Reports Third Quarter 2016 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Nov 09, 2016, 01:25 ET XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Sep 27, 2016, 08:30 ET XTL Biopharmaceuticals Reports Second Quarter 2016 Financial Results & Provides Clinical and Operational Update

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Sep 07, 2016, 08:32 ET XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Sep 06, 2016, 08:00 ET XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...


Aug 11, 2016, 09:00 ET XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1

XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company developing its lead...